Rezolute, Inc.

The momentum for this stock is not very good. Rezolute, Inc. is not very popular among insiders. Tradey thinks it is not wise to invest in Rezolute, Inc..

News

Rezolute, Inc. (NASDAQ:RZLT) Given Average Rating of "Buy" by Brokerages

Zolmax Shares of Rezolute, Inc. (NASDAQ:RZLT - Get Free Report) have earned an average recommendation of "Buy" from the eight analysts that are presently covering the company, MarketBeat Ratings reports...\n more…

Rezolute (NASDAQ:RZLT) Given New $15.00 Price Target at BTIG Research

Ticker Report Rezolute (NASDAQ:RZLT - Free Report) had its price target lifted by BTIG Research from $13.00 to $15.00 in a research note published on Tuesday, Benzinga reports. The brokerage currently has a buy...\n more…

Rezolute (NASDAQ:RZLT) Stock Rating Reaffirmed by HC Wainwright

Ticker Report Rezolute (NASDAQ:RZLT - Get Free Report)s stock had its "buy" rating reiterated by investment analysts at HC Wainwright in a note issued to investors on Monday, Benzinga reports. They...\n more…

Rezolute Gains 13%, Insider Trades Reap Benefit

Simply Wall St Insiders who bought Rezolute, Inc. ( NASDAQ:RZLT ) stock in the last 12 months were richly rewarded last week. The...\n more…

Rezolute clinical hold removal 'best case scenario,' says H.C. Wainwright

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

FDA Gives Green Signal To Rezolute's Genetic Disorder Treatment

Benzinga FDA lifts clinical hold on Rezolute's RZ358 for treating congenital hyperinsulinism, allowing U.S. participants in Phase 3 study. Enrollment expected to start in 2025 with topline data by mid-year.\n more…